csirt@kutim:~/threat-intel/cve/CVE-2023-53168

Katalog CVE

CVSS 5.5 · Medium EPSS 0,16%

Kerentanan NULL Pointer Dereference pada linux kernel. Skor CVSS 3.1 5.5 (Medium) menurut NVD.

Deskripsi (NVD)

In the Linux kernel, the following vulnerability has been resolved: usb: ucsi_acpi: Increase the command completion timeout Commit 130a96d698d7 ("usb: typec: ucsi: acpi: Increase command completion timeout value") increased the timeout from 5 seconds to 60 seconds due to issues related to alternate mode discovery. After the alternate mode discovery switch to polled mode the timeout was reduced, but instead of being set back to 5 seconds it was reduced to 1 second. This is causing problems when using a Lenovo ThinkPad X1 yoga gen7 connected over Type-C to a LG 27UL850-W (charging DP over Type-C). When the monitor is already connected at boot the following error is logged: "PPM init failed (-110)", /sys/class/typec is empty and on unplugging the NULL pointer deref fixed earlier in this series happens. When the monitor is connected after boot the following error is logged instead: "GET_CONNECTOR_STATUS failed (-110)". Setting the timeout back to 5 seconds fixes both cases.

Rincian

Terbit di NVD
15 September 2025
Terakhir diubah
17 Juni 2026
Status NVD
Analyzed
CVSS 3.1
5.5 (Medium), sumber NVD
CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-476: NULL Pointer Dereference
EPSS (30 hari)
0,16% peluang dieksploitasi; lebih tinggi dari 4,3% CVE lain

Produk dan versi terdampak

VendorProdukVersi terdampak
linux linux kernel Versi 5.16 hingga sebelum 6.1.22
linux linux kernel Versi 6.2 hingga sebelum 6.2.9
linux linux kernel Versi 6.3 rc1
linux linux kernel Versi 6.3 rc2
linux linux kernel Versi 6.3 rc3

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:10 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.